Highlights from the Ratings and Financial Report for Aerie Pharmaceuticals Inc. (AERI) – News Heater
Home  »  Trending   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Aerie Pharmaceuticals Inc. (AERI)

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) went up by 9.88% from its latest closing price compared to the recent 1-year high of $19.26. The company’s stock price has collected -16.45% of loss in the last five trading sessions.

Is It Worth Investing in Aerie Pharmaceuticals Inc. (NASDAQ :AERI) Right Now?

Plus, the 36-month beta value for AERI is at 0.76.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


AERI currently public float of 42.98M and currently shorts hold a 13.09% ratio of that float. Today, the average trading volume of AERI was 800.02K shares.

AERI’s Market Performance

AERI stocks went down by -16.45% for the week, with a monthly drop of -17.52% and a quarterly performance of -5.70%, while its annual performance rate touched -63.91%. The volatility ratio for the week stands at 13.33% while the volatility levels for the past 30 days are set at 8.77% for Aerie Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -14.75% for AERI stocks with a simple moving average of -36.15% for the last 200 days.

Analysts’ Opinion of AERI

Many brokerage firms have already submitted their reports for AERI stocks, with BofA Securities repeating the rating for AERI by listing it as a “Underperform.” The predicted price for AERI in the upcoming period, according to BofA Securities is $9 based on the research report published on October 19th of the previous year 2020.

Guggenheim, on the other hand, stated in their research note that they expect to see AERI reach a price target of $20. The rating they have provided for AERI stocks is “Buy” according to the report published on September 08th, 2020.

Needham gave a rating of “Buy” to AERI, setting the target price at $26 in the report published on August 07th of the previous year.

AERI Trading at -21.57% from the 50-Day Moving Average

After a stumble in the market that brought AERI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.51% of loss for the given period.

Volatility was left at 8.77%, however, over the last 30 days, the volatility rate increased by 13.33%, as shares sank -26.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.67% lower at present.

During the last 5 trading sessions, AERI fell by -16.45%, which changed the moving average for the period of 200-days by -59.76% in comparison to the 20-day moving average, which settled at $7.45. In addition, Aerie Pharmaceuticals Inc. saw -8.12% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for AERI

Equity return is now at value 213.50, with -19.90 for asset returns.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam